Drug intelligence / Profile preview

gentamicin + imipenem

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

A combination antibiotic regimen consisting of gentamicin (an aminoglycoside) and imipenem (a carbapenem). This combination provides broad-spectrum coverage against both gram-positive and gram-negative bacteria. Gentamicin works by binding to bacterial ribosomes and inhibiting protein synthesis, while imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. The combination has been studied for potential synergistic effects, particularly against methicillin-resistant Staphylococcus aureus (MRSA).

Targets

Bacterial RibosomePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on gentamicin + imipenem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gentamicin + imipenem.

Explore the full profile